GBT Global Blood Therapeutics, Inc. Stock Quote

GBT [NASD]

Index	-	P/E	-	EPS (ttm)	-5.00	Insider Own	1.90%	Shs Outstand	65.59M	Perf Week	0.66%
Market Cap	4.51B	Forward P/E	-	EPS next Y	-2.85	Insider Trans	-0.25%	Shs Float	61.77M	Perf Month	86.27%
Income	-322.50M	PEG	-	EPS next Q	-1.11	Inst Own	-	Short Float	15.16%	Perf Quarter	161.57%
Sales	234.90M	P/S	19.20	EPS this Y	-19.30%	Inst Trans	3.98%	Short Ratio	3.54	Perf Half Y	117.66%
Book/sh	1.80	P/B	37.24	EPS next Y	39.10%	ROA	-39.20%	Target Price	66.63	Perf Year	142.02%
Cash/sh	7.69	P/C	8.72	EPS next 5Y	37.00%	ROE	-170.40%	52W Range	21.65 - 73.02	Perf YTD	129.04%
Dividend	-	P/FCF	-	EPS past 5Y	-14.20%	ROI	-37.10%	52W High	-8.19%	Beta	0.90
Dividend %	-	Quick Ratio	6.20	Sales past 5Y	-	Gross Margin	98.10%	52W Low	209.65%	ATR	3.00
Employees	457	Current Ratio	6.90	Sales Q/Q	50.40%	Oper. Margin	-	RSI (14)	90.19	Volatility	0.51% 6.34%
Optionable	Yes	Debt/Eq	4.91	EPS Q/Q	-12.60%	Profit Margin	-	Rel Volume	2.02	Prev Close	66.75
Shortable	Yes	LT Debt/Eq	4.91	Earnings	Aug 08 AMC	Payout	-	Avg Volume	2.64M	Price	67.04
Recom	1.90	SMA20	51.62%	SMA50	90.45%	SMA200	111.25%	Volume	5,347,002	Change	0.43%

Aug-08-22

Upgrade

Canaccord Genuity

Hold → Buy

$40 → $72

Aug-08-22

Downgrade

William Blair

Outperform → Mkt Perform

Mar-28-22

Resumed

Wedbush

Outperform

$138 → $71

Dec-07-21

Upgrade

William Blair

Mkt Perform → Outperform

Oct-07-21

Initiated

Jefferies

Buy

$68

Aug-04-21

Upgrade

Truist

Hold → Buy

$50

Jun-28-21

Downgrade

JP Morgan

Overweight → Neutral

$70 → $36

Apr-14-21

Initiated

SVB Leerink

Outperform

$54

Mar-12-21

Initiated

Wolfe Research

Outperform

$67

Feb-25-21

Downgrade

William Blair

Outperform → Mkt Perform

Jan-20-21

Downgrade

Piper Sandler

Overweight → Neutral

$75 → $50

Dec-15-20

Resumed

H.C. Wainwright

Buy

$75

Dec-03-20

Initiated

RBC Capital Mkts

Outperform

$75

Nov-06-20

Downgrade

Raymond James

Outperform → Mkt Perform

Oct-06-20

Initiated

Evercore ISI

Outperform

$102

Aug-25-20

Initiated

Raymond James

Outperform

$115

Jul-20-20

Initiated

ROTH Capital

Buy

$129

Jul-13-20

Initiated

BofA Securities

Buy

$92

Jul-01-20

Upgrade

Goldman

Neutral → Buy

$91 → $103

Apr-28-20

Initiated

Stifel

Buy

$112

Aug-12-22 09:50AM	Pharma Stock Roundup: PFE to Buy GBT, JNJ to Stall Baby Talc Sale Globally From 2023 Zacks
Aug-09-22 04:46PM	Get ready for more merger mania in the pharma sector for the rest of the year MarketWatch
03:59PM	As Covid Vaccine Boom Ends, Pfizer and Moderna Pursue Opposite Strategies Barrons.com
11:02AM	Global Blood (GBT) to be Acquired by Pfizer, Misses on Earnings Zacks
Aug-08-22 04:07PM	Why Pfizer's $5.4 Billion GBT Takeover Is 'Mutually Beneficial' Investor's Business Daily
02:51PM	Why Global Blood Therapeutics Stock Was Trouncing the Market Today Motley Fool
12:58PM	Pfizer Agrees to $5.4 Billion Deal for Global Blood Therapeutics The Wall Street Journal
12:07PM	Stock Market Gains On Tax, Climate, Health Care Bill; 6 Breakouts Amid Mixed Week Of Earnings Investor's Business Daily
11:48AM	Karunas Schizophrenia-Trial Data Are Best Case Scenario for the Biotech Stock Barrons.com
11:09AM	Pfizer to buy Peninsula sickle cell disease drug maker for $5.4 billion American City Business Journals
10:05AM	Biotech Wins Last Week: 5 Best ETFs Zacks
08:07AM	Pfizer Scoops Up Sickle Disease Player For $5B Benzinga
07:22AM	Tesla, Palantir, Berkshire Hathaway and More Stock Market Movers Monday Barrons.com
06:57AM	UPDATE 4-Flush with cash, Pfizer buys Global Blood Therapeutics in $5.4 bln deal Reuters
06:52AM	Pfizer confirms to acquire Global Blood Therapeutics for $5.4 billion in deal that gives it access to sickle-cell disease treatment MarketWatch
06:48AM	Pfizer to boost pipeline with $5.4 billion Global Blood Therapeutics buy Reuters
06:48AM	Flush with cash, Pfizer buys Global Blood Therapeutics in $5.4 billion deal Reuters
06:45AM	Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology GlobeNewswire
06:37AM	Pfizer agrees to buy Global Blood Therapeutics in deal valued at $5.4 billion: WSJ MarketWatch
Aug-05-22 05:22PM	Pfizer in Advanced Talks to Buy Global Blood Therapeutics for About $5 Billion The Wall Street Journal +33.03%
04:49PM	Stock Market Ends Upbeat Week With Mixed Results On Hot Job Numbers Investor's Business Daily
04:11PM	Pfizer Is Reportedly In 'Advanced Talks' To Buy Global Blood Therapeutics For $5 Billion Investor's Business Daily
01:35PM	Why Global Blood Therapeutics Stock Is Vaulting Higher Today Motley Fool
01:09PM	Pfizer in Talks to Buy Sickle-Cell Drugmaker for $5 Billion, WSJ Reports Bloomberg
12:20PM	Pfizer, Global Blood Therapeutics In Advanced Talks For $5B Buyout Deal: Report Benzinga
12:08PM	Pfizer in Talks to Buy Global Blood Therapeutics for $5 Billion, Report Says Barrons.com
11:58AM	WSJ: Pfizer considering buying Global Blood Therapeutics for roughly $5 billion MarketWatch
11:44AM	Pfizer in advanced talks to buy Global Blood Therapeutics for $5 billion - WSJ Reuters
07:53AM	Strength Seen in Global Blood (GBT): Can Its 41.4% Jump Turn into More Strength? Zacks
Aug-04-22 04:05PM	GBT Announces New Employment Inducement Grants GlobeNewswire +41.44%
02:42PM	Why Global Blood Therapeutics Stock Is Soaring Today Motley Fool
10:44AM	Stock Market Lower As Crude Oil Prices Fall Below $90 Investor's Business Daily
09:07AM	Global Blood Therapeutics shares jump 34% after Bloomberg report about 'takeover interest' MarketWatch
Aug-03-22 04:05PM	GBT Announces Participation at the Wedbush PacGrow Healthcare Conference GlobeNewswire
Jul-31-22 09:35AM	7 Small-Cap Growth Stocks With 1,000% Upside Potential InvestorPlace
Jul-29-22 08:00AM	GBT to Announce Second Quarter 2022 Financial Results on Monday, August 8, 2022 GlobeNewswire
Jul-27-22 10:01AM	Analysts Estimate Regeneron (REGN) to Report a Decline in Earnings: What to Look Out for Zacks
Jul-26-22 10:01AM	Earnings Preview: Global Blood Therapeutics (GBT) Q2 Earnings Expected to Decline Zacks
03:01AM	MHRA Grants Marketing Authorization for GBTs Oxbryta® (voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older GlobeNewswire
Jul-14-22 08:00AM	GBT Initiates Expanded Access Program for Voxelotor in Patients With Sickle Cell Disease in Brazil GlobeNewswire
Jul-13-22 08:00AM	The GBT Foundation Awards $250,000 in ACE Grants to Support Sickle Cell Disease Community-Based Organizations GlobeNewswire
Jul-07-22 04:05PM	GBT Announces New Employment Inducement Grants GlobeNewswire
Jul-05-22 03:55PM	Global Blood Therapeutic Stock Sees Relative Strength Rating Rise To 91 Investor's Business Daily
Jun-30-22 11:47AM	Global Blood (GBT) Initiates Phase II Study on SCD Candidate Zacks
Jun-29-22 03:27PM	Why Global Blood Therapeutics Trended Upward Today Motley Fool +8.18%
08:00AM	GBT Initiates Phase 2/3 Clinical Trial of GBT601 in Patients with Sickle Cell Disease GlobeNewswire
Jun-16-22 08:00AM	NFL Running Back Tevin Coleman and Family Team Up with GBT to Share Playbook for Families Affected by Sickle Cell Disease GlobeNewswire
Jun-13-22 08:00AM	New GBT Multinational Survey Shines a Needed Light on the Misunderstood Realities, Unseen Burden and Care Challenges of Sickle Cell Disease GlobeNewswire
Jun-10-22 04:06PM	How Global Blood Therapeutics Thinks It Can Take On Crispr's Gene Editing Investor's Business Daily
03:00AM	GBT Presents Positive New Real-World Evidence Data at EHA2022 Congress Further Supporting Clinical Use of Oxbryta® (voxelotor) in Sickle Cell Disease GlobeNewswire
Jun-09-22 09:58AM	7 No-Brainer Biotech Stocks to Add to Your Buy List InvestorPlace -5.73%
Jun-08-22 11:30AM	Why Is CRISPR Therapeutics AG (CRSP) Up 45.9% Since Last Earnings Report? Zacks
Jun-07-22 11:23AM	Global Blood's (GBT) Candidates for SCD Get Two FDA Tags Zacks
Jun-06-22 10:00AM	The GBT Foundation Opens 2022 ACCEL Grant Program to Provide Up to $500,000 in Support to Sickle Cell Disease Nonprofit Healthcare Organizations and Institutions GlobeNewswire -6.97%
08:00AM	GBTs Inclacumab and GBT601 Receive U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for the Treatment of Sickle Cell Disease GlobeNewswire
Jun-03-22 11:32AM	Global Blood (GBT) Down 15.5% Since Last Earnings Report: Can It Rebound? Zacks
Jun-02-22 04:05PM	GBT Announces New Employment Inducement Grants GlobeNewswire
Jun-01-22 04:05PM	GBT to Host Investor Conference Call on Friday, June 10 and Participate in Upcoming Investor Conferences GlobeNewswire
May-26-22 11:18AM	Global Blood (GBT) Thrives on Oxbryta, Overdependence a Woe Zacks
May-12-22 10:00AM	GBT Announces Five Data Presentations on Sickle Cell Disease at Upcoming EHA2022 Congress GlobeNewswire
May-11-22 10:24AM	Shareholders in Global Blood Therapeutics (NASDAQ:GBT) have lost 58%, as stock drops 24% this past week Simply Wall St. -5.28%
May-05-22 06:40PM	Why Global Blood Therapeutics Stock Was Sickly Today Motley Fool -7.96%
04:05PM	GBT Announces Participation in Upcoming Investor Conferences GlobeNewswire
04:05PM	GBT Announces New Employment Inducement Grants GlobeNewswire
10:22AM	Global Blood (GBT) Q1 Loss Narrower Than Expected, Revenues Lag Zacks
May-04-22 11:30PM	Global Blood Therapeutics (GBT) Q1 2022 Earnings Call Transcript Motley Fool
05:25PM	Global Blood Therapeutics (GBT) Reports Q1 Loss, Lags Revenue Estimates Zacks
04:05PM	GBT Reports First Quarter 2022 Financial Results GlobeNewswire
Apr-28-22 08:20AM	GBT Launches Inaugural Environmental, Social and Governance (ESG) Report GlobeNewswire
Apr-27-22 03:03PM	Analysts Estimate Global Blood Therapeutics (GBT) to Report a Decline in Earnings: What to Look Out for Zacks
08:00AM	GBT to Announce First Quarter 2022 Financial Results on Wednesday, May 4, 2022 GlobeNewswire
Apr-11-22 02:35PM	A Look At The Intrinsic Value Of BMTC Group Inc. (TSE:GBT) Simply Wall St.
Apr-08-22 11:22AM	BMTC GROUP INC. ANNOUNCES THE RENEWAL OF ITS NORMAL COURSE ISSUER BID TO ACQUIRE COMMON SHARES CNW Group
Apr-07-22 04:05PM	GBT Announces New Employment Inducement Grants GlobeNewswire
Apr-06-22 02:30AM	Guerbet strengthens its Executive Committee with the appointment of Charlotte Bamière, General Counsel GlobeNewswire
Apr-03-22 09:10PM	3 Strong Buy Stocks to Watch as 2Q22 Kicks Off TipRanks
Mar-29-22 03:17PM	Gadopiclenol Marketing Authorization dossier submissions accepted for review by EMA and FDA PR Newswire
12:06PM	Guerbet - Gadopiclenol Marketing Authorization dossier submissions accepted for review by EMA and FDA - Priority Review granted by US-FDA March 28, 2022 GlobeNewswire
Mar-25-22 11:30AM	Global Blood (GBT) Up 15.4% Since Last Earnings Report: Can It Continue? Zacks
Mar-24-22 04:05PM	GBT Announces Participation at the Guggenheim Genomic Medicines & Rare Disease Day GlobeNewswire
Mar-23-22 12:45PM	Guerbet: 2021 annual results GlobeNewswire
Mar-10-22 04:05PM	GBT Announces New Employment Inducement Grants GlobeNewswire
Mar-03-22 08:00AM	The GBT Foundation Opens 2022 ACE Grant Program, Providing up to $250,000 in Support to Sickle Cell Disease Community-Based Organizations GlobeNewswire
Mar-01-22 11:00AM	Biotech leaders call for companies to cut ties to Russia following invasion of Ukraine American City Business Journals
Feb-28-22 08:00AM	GBT Announces Participation in Upcoming Investor Conferences GlobeNewswire
Feb-24-22 11:14AM	Global Blood's (GBT) Q4 Earnings Miss Mark, Revenues Rise Y/Y Zacks
Feb-23-22 05:25PM	Global Blood Therapeutics (GBT) Reports Q4 Loss, Tops Revenue Estimates Zacks -7.82%
04:05PM	GBT Reports Fourth Quarter and Full Year 2021 Financial Results GlobeNewswire
Feb-22-22 12:01PM	Drug/Biotech Stocks' Q4 Earnings on Feb 23: BMRN, BHC & More Zacks
Feb-16-22 04:05PM	GBT to Announce Fourth Quarter and Full Year 2021 Financial Results on Wednesday, February 23, 2022 GlobeNewswire +7.52%
09:41AM	Global Blood Therapeutics' Oxbryta Scores European Approval For Sickle Cell Disease Benzinga
06:00AM	European Commission Approves Oxbryta® (voxelotor) for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older GlobeNewswire
Feb-08-22 06:46AM	Is Global Blood Therapeutics (NASDAQ:GBT) Using Debt In A Risky Way? Simply Wall St.
Feb-03-22 08:00AM	GBT Announces New Employment Inducement Grants GlobeNewswire
Jan-27-22 03:00AM	Positive Early Access to Medicines Scheme (EAMS) Scientific Opinion Awarded to GBTs Voxelotor for the Treatment of Haemolytic Anaemia Due to Sickle Cell Disease GlobeNewswire
Jan-10-22 08:00AM	Oxbryta® (voxelotor) Tablets for Oral Suspension, A New Dispersible Tablet Dosage Form, Now Available for Patients with Sickle Cell Disease in the United States GlobeNewswire
Jan-07-22 04:49PM	Oppenheimer Bullish on These 2 Stocks for 70% Upside (Or More) TipRanks
Jan-06-22 08:00AM	GBT Announces New Employment Inducement Grants GlobeNewswire
Jan-04-22 08:00AM	GBT to Present at the 40th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-23-21 05:52PM	A Peninsula biotech's FDA approval could shift the health prognosis for people of color American City Business Journals

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Svoronos Dawn	Director	Jun 21	Sale	27.24	1,908	51,983	5,376	Jun 22 06:00 PM
Pizzo Philip A.	Director	Jun 21	Sale	27.25	1,260	34,337	9,112	Jun 22 06:00 PM
Morrison Scott W	Director	Sep 09	Sale	30.21	4,800	145,003	3,037	Sep 10 08:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience